One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: The APOLLO study

Yuji Oshima, Kenichi Kimoto, Noriko Yoshida, Kimihiko Fujisawa, Shozo Sonoda, Toshiaki Kubota, Toshinori Murata, Taiji Sakamoto, Shigeo Yoshida, Koh Hei Sonoda, Tatsuro Ishibashi

研究成果: Contribution to journalArticle査読

17 被引用数 (Scopus)

抄録

Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naïve PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6% of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001). Mean central foveal thickness decreased from 356 to 239 μm (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5% after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients.

本文言語英語
ページ(範囲)163-171
ページ数9
ジャーナルOphthalmologica
238
3
DOI
出版ステータス出版済み - 9 1 2017

All Science Journal Classification (ASJC) codes

  • 眼科学
  • 感覚系

フィンガープリント

「One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: The APOLLO study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル